Principal Investigator:
Sheilagh Maguiness, MD – University of Minnesota
Overview:
There are growing reports regarding the efficacy of oral M-TOR inhibitors such as sirolimus in the treatment of complex combined vascular malformations. There is strong rationale for the use of sirolimus/M-TOR inhibitors in this setting given the genetic basis for many vascular malformations (including lymphatic malformations) which involve the PIK3CA signaling pathway. The use of topical sirolimus preparations have also been reported useful in the setting of facial angiofibromas and capillary malformations . We gathered retrospective data on the use of topical sirolimus for treatment of superficial vascular anomalies.
Status:
Manuscript submitted for publication.